CD8A and neoplasm: The number of E7-specific CD8+ T lymphocytes increased in the tumour microenvironment with those therapies that increased the total number of CD8+ T lymphocytes: E7 long peptide, E7 long peptide/PIC and triple therapy (Fig. 5a).